AI is about to change healthcare. These 8 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own UBE, you really need to believe that a mature chemicals group with modest earnings growth and flat-to-soft revenue can still create value through disciplined capital allocation and a shareholder-friendly payout. The latest guidance for a sharply higher dividend, reaffirmed in August 2026, reinforces that income angle and suggests management is comfortable sharing more of today’s earnings, even as revenue forecasts point to gentle decline and return on equity remains low. In the near term, that higher yield potential could be a supporting catalyst for the share price after an already strong 12‑month run, but it does not fundamentally change the key risk debate around cash flow coverage, debt comfort and whether current profitability is resilient if demand weakens further.
However, one key funding risk behind this generous dividend profile deserves closer attention from investors. UBE's share price has been on the slide but might be dropping deeper into value territory. Find out whether it's a bargain at this price.Two fair value views from the Simply Wall St Community span from about ¥1,247 to ¥3,400, underlining how far apart individual estimates can be. Set against UBE’s richer dividend guidance and only moderate profit growth outlook, these contrasting opinions give you a sense of how differently investors weigh income appeal against balance sheet and cash flow pressures, and why it is worth exploring several viewpoints before forming a conviction.
Explore 2 other fair value estimates on UBE - why the stock might be worth less than half the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Opportunities like this don't last. These are today's most promising picks. Check them out now:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com